NCT05083754View on ClinicalTrials.gov

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Glioblastoma Multiforme

Interventions

DRUG

Retifanlimab

Anti-PD-1 Therapy

DRUG

Temozolomide

Anti-PD-1 Therapy

RADIATION

Radiation Therapy

Standard of Care

Trial Locations (1)

21287

RECRUITING

Johns Hopkins Medical Institution, Baltimore

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER